Internal Medicine, Medical Oncology · Glendale, AZ
NPI
1992729826
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
5601 W Eugie Ave Ste 106
Glendale, AZ, 85304
Phone (602) 978-6255
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.1M
80,821 services
Medicare patients, 2024
439
Average age 75
Drug cost, 2024
$6.6M
1,284 prescriptions
Company payments, 2025
$3,140
From 38 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Martin B Langford was code J1642 (injection, heparin sodium, (heparin lock flush), per 10 units), 5,280 times for 20 patients. In total Martin B Langford billed 80,821 services in 85 codes, and Medicare paid $1.1M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-07-09.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1642 Injection, heparin sodium, (heparin lock flush), per 10 units | Office | 5,280 | 20 | $0.01 | $64.91 |
| 88185 Surgical Pathology Examination | Office | 895 | 31 | $15.94 | $14K |
| 85025 Blood Count | Office | 682 | 214 | $7.59 | $5,175 |
| 36415 Venipuncture Blood Collection | Office | 563 | 217 | $8.63 | $4,861 |
| 99214 Office E&M - Established | Office | 354 | 215 | $89.67 | $32K |
| 99215 Office E&M - Established | Office | 272 | 158 | $127.92 | $35K |
| 96372 Injection Administration | Office | 255 | 28 | $10.78 | $2,750 |
| 99233 Hospital E&M - Subsequent | Facility | 209 | 100 | $90.75 | $19K |
| 96413 Chemotherapy Administration | Office | 188 | 15 | $95.06 | $18K |
| 96367 Intravenous Infusion, Hydration | Office | 110 | 12 | $21.45 | $2,360 |
| 96375 Injection Administration | Office | 109 | 15 | $11.68 | $1,273 |
| 99232 Hospital E&M - Subsequent | Facility | 92 | 58 | $60.02 | $5,522 |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 70 | 11 | $0.93 | $65.15 |
| 99223 Hospital E&M - Initial | Facility | 61 | 61 | $133.17 | $8,123 |
| 96365 Intravenous Infusion, Hydration | Office | 59 | 21 | $46.39 | $2,737 |
By year: 2022 $1.5M for 94,132 services; 2023 $1.3M for 109,488 services; 2024 $1.1M for 80,821 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88185 Surgical Pathology Examination | 895 | 31 | $15.94 | $14K |
| 85025 Blood Count | 682 | 214 | $7.59 | $5,175 |
| 36415 Venipuncture Blood Collection | 563 | 217 | $8.63 | $4,861 |
| 88184 Surgical Pathology Examination | 33 | 31 | $59.84 | $1,975 |
Medicare prescription drug claims, 2024
In 2024, the drug Martin B Langford prescribed most often to Medicare patients was Eliquis (Apixaban), with 206 prescriptions and refills. In total Martin B Langford wrote 1,284 Medicare prescriptions that cost $6.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 206 | 355 | 62 | $208K |
| Anastrozole Generic | 88 | 238 | 26 | $2,255 |
| Jakafi Ruxolitinib Phosphate | 79 | 79 | Under 11 | $1.6M |
| Calquence Acalabrutinib Maleate | 58 | 58 | Under 11 | $862K |
| Prednisone Generic | 56 | 84 | 15 | $273 |
| Warfarin Sodium Generic | 48 | 78 | Under 11 | $273 |
| Hydroxyurea Generic | 47 | 99 | 11 | $1,190 |
| Procrit Epoetin Alfa | 40 | 40 | Under 11 | $73K |
| Abiraterone Acetate Generic | 30 | 30 | Under 11 | $72K |
| Dexamethasone Generic | 25 | 28 | 11 | $478 |
| Brukinsa Zanubrutinib | 24 | 24 | Under 11 | $351K |
| Levothyroxine Sodium Generic | 24 | 46 | Under 11 | $250 |
| Xtandi Enzalutamide | 23 | 23 | Under 11 | $348K |
| Oxycodone Hcl Generic | 23 | 23 | Under 11 | $455 |
| Fulvestrant Generic | 22 | 22 | Under 11 | $2,702 |
Brand drugs: 684 claims; generic drugs: 600 claims; opioid claims: 28.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Martin B Langford $3,140 ($3,140 in general payments such as food, travel and fees) from 38 companies. The largest payer was Novartis Pharmaceuticals Corporation with $324.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 14 | $324 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $269 |
| Pfizer Inc. PFE | 12 | $261 |
| Celgene Corporation BMY | 10 | $251 |
| Merck Sharp & Dohme LLC MRK | 7 | $200 |
| Janssen Biotech, Inc. JNJ | 6 | $131 |
| Genzyme Corporation SNY | 4 | $122 |
| Daiichi Sankyo Inc. 4568.T | 4 | $118 |
| Abbvie Inc. ABBV | 5 | $117 |
| Genmab U.S., Inc. GMAB | 4 | $110 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.